|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01332 TOUYUN BIOTECH
Nominal 
0.154 -0.015 (-8.876%) | 2024/06 - Interim HKD(K$) | %Chg (Compare to Interim) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | 2020/12 HKD(K$) | |
| Turnover | 73,047 | -29.995% | 198,032 | 323,334 | 291,415 | 218,805 |
| Cost of Sales | (41,108) | -39.933% | (142,036) | (195,706) | (176,451) | (122,172) |
| Gross Profit | 31,939 | -11.053% | 55,996 | 127,628 | 114,964 | 96,633 |
| 2024/06 - Interim HKD(K$) | %Chg (Compare to Interim) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | 2020/12 HKD(K$) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | (166) | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | (24,458) | |
| Profit / (Loss) before Taxation | (49,145) | -42.237% | (272,585) | (199,183) | (122,970) | (171,983) | |
| Taxation | 326 | -- | 16 | (3,473) | (971) | (6) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 850 | -26.215% | 3,630 | 4,591 | 50,993 | 3,213 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (47,969) | -42.861% | (268,939) | (198,065) | (72,948) | (168,776) | |
| 2024/06 - Interim HKD(K$) | %Chg (Compare to Interim) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | 2020/12 HKD(K$) | |
| Net Finance Costs / (Income) | 4,424 | 8.008% | 7,292 | 21,553 | 16,970 | 31,703 |
| Depreciation & Amortisation | 17,148 | -10.594% | 36,585 | 33,138 | 22,700 | 28,449 |
| Directors' Emoluments | -- | -- | 7,022 | 7,473 | 7,195 | 4,751 |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | N/A | -- | Disclaimer | Unqualified (Modified Report) | Disclaimer | Unqualified |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | -1.710 | -42.809% | -9.580 | -7.060 | -2.610 | -6.320 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 0.001 | (0.009) | (0.019) | (0.006) |
| NBV per share ($) | (0.017) | -- | 0.000 | 0.094 | 0.167 | 0.176 |
| Remarks: | Real time quote last updated: 14/11/2024 15:31 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders ($) | HKD -47,969,000 |
| %Change | -42.861% |
| EPS / (LPS) | HKD -0.017 |
| NBV Per Share ($) | HKD -0.017 |